Wall Street can't stop talking about this potential 'baby-Valeant' - Business Insider

Business Insider

Wall Street can't stop talking about this potential 'baby-Valeant' Business Insider And they're looking everywhere in the market for companies that may share Valeant's losing business strategy of using debt-funded acquisitions to grow their product line (rather than R&D), and then jack up the price of those acquired drugs. Enter ... and more »